Advertisement

Tumor Biology

, Volume 35, Issue 5, pp 5007–5011 | Cite as

Preoperative serum LMTK3 as a novel biomarker in non-small cell lung cancer

Research Article

Abstract

The lemur tyrosine kinase-3 (LMTK3) has been reported to be involved in tumor progression. The aim of this study was to determine the diagnostic and prognostic significances of preoperative serum LMTK3 in non-small cell lung cancer (NSCLC) patients. Sera were collected from 100 healthy volunteers (HV), 280 benign lung diseases (BLD) patients, and 524 NSCLC patients prior to operation. The serum LMTK3 level was detected by ELISA. We found that serum LMTK3 level was markedly elevated in NSCLC patients compared with controls. The receiver operating characteristic (ROC) curve suggests that serum LMTK3 is a good diagnostic and differential marker for discriminating NSCLC patients from BLD. NSCLC patients with LMTK3 level ≥6.85 ng/ml had significantly worse survival than patients with LMTK3 <6.85 ng/ml. In multivariate analysis, LMTK3 level ≥6.85 ng/ml was an independent factor of poor prognosis [hazard ratio (HR) = 2.95; p = 0.011] after adjusting for age, sex, smoking behavior, stage, and histology. The Kaplan–Meier survival curves showed the consistent trend. Preoperative serum LMTK3 is a novel diagnostic and independent prognostic biomarker in patients with NSCLC.

Keywords

Non-small cell lung cancer LMTK3 Diagnosis Prognosis Biomarker 

Notes

Conflicts of interest

None

References

  1. 1.
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.CrossRefPubMedGoogle Scholar
  2. 2.
    López-González A, Ibeas Millán P, Cantos B, Provencio M. Surveillance of resected non-small cell lung cancer. Clin Transl Oncol. 2012;14:721–5.CrossRefPubMedGoogle Scholar
  3. 3.
    Zarogoulidis K, Zarogoulidis P, Darwiche K, Boutsikou E, Machairiotis N, Tsakiridis K, et al. Treatment of non-small cell lung cancer (NSCLC). J Thorac Dis. 2013;5:S389–96.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Filipits M, Pirker R. Predictive markers in the adjuvant therapy of non-small cell lung cancer. Lung Cancer. 2011;74:355–63.CrossRefPubMedGoogle Scholar
  5. 5.
    Indovina P, Marcelli E, Maranta P, Tarro G. Lung cancer proteomics: recent advances in biomarker discovery. Int J Proteomics. 2011;2011:726869.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non- small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol. 2010;28:744–52.CrossRefPubMedGoogle Scholar
  7. 7.
    Tufman A, Huber RM. Biological markers in lung cancer: a clinician’s perspective. Cancer Biomark. 2010;6:123–35.CrossRefPubMedGoogle Scholar
  8. 8.
    Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 2012;76:138–43.CrossRefPubMedGoogle Scholar
  9. 9.
    Bharti A, Ma PC, Salgia R. Biomarker discovery in lung cancer—promises and challenges of clinical proteomics. Mass Spectrom Rev. 2007;26:451–66.CrossRefPubMedGoogle Scholar
  10. 10.
    Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene. 2000;19:5548–57.CrossRefPubMedGoogle Scholar
  11. 11.
    Giamas G, Filipović A, Jacob J, Messier W, Zhang H, Yang D, et al. Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nat Med. 2011;17:715–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Zhao G, Guo J, Li D, Jia C, Yin W, Sun R, et al. MicroRNA-34a suppresses cell proliferation by targeting LMTK3 in human breast cancer MCF-7 cell line. DNA Cell Biol. 2013;32(12):699–707.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Naik S, Dothager RS, Marasa J, Lewis CL, Piwnica-Worms D. Vascular endothelial growth factor receptor-1 is synthetic lethal to aberrant {beta}-catenin activation in colon cancer. Clin Cancer Res. 2009;15:7529–37.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Kang DW, Choi KY, Min do S. Phospholipase D meets Wnt signaling: a new target for cancer therapy. Cancer Res. 2011;71:293–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/American thoracic society/European respiratory society: international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244–85.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Vallières E, Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, et al. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4:1049–59.CrossRefPubMedGoogle Scholar
  17. 17.
    Wakatsuki T, LaBonte MJ, Bohanes PO, Zhang W, Yang D, Azuma M, et al. Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States. Mol Cancer Ther. 2013;12:2261–72.CrossRefPubMedGoogle Scholar
  18. 18.
    Shi H, Wu J, Ji M, Zhou Q, Li Z, Zheng X, et al. Serum lemur tyrosine kinase 3 expression in colorectal cancer patients predicts cancer progression and prognosis. Med Oncol. 2013;30:754.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Fourth Department of OncologyShengjing Hospital of China Medical UniversityShenyangChina

Personalised recommendations